Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
Clinical trial NCT02739386 · COMPLETED
Trial details
- NCT number
- NCT02739386
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2016-02-29
- Primary completion
- 2017-03-30
- Enrollment
- 370
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.